Stocklytics Platform
Supernus Pharmaceuticals
SUPN63
$31.26arrow_drop_up0.38%$0.11
NASDAQ - As of Mar 15, 6:05 PM EDT Market Closed
High Growth
SUPN63

$31.26

arrow_drop_up0.38%

Performance History

Chart placeholder
Key Stats
Open$31.31
Prev. Close$31.17
EPS1.32
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.74B
PE Ratio23.68
LOWHIGH
Day Range28.41
34.04
52 Week Range21.99
42.50

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$813.48
Perf. (24h)arrow_drop_up1.30%$10.47
Market Cap$730.64B
Price$488.65
Perf. (24h)arrow_drop_up0.93%$4.48
Market Cap$451.22B
Price$162.81
Perf. (24h)arrow_drop_down0.24%-$0.40
Market Cap$397.30B
Price$211.77
Perf. (24h)arrow_drop_up0.21%$0.44
Market Cap$373.84B

About Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals Inc. (SUPN) is a pharmaceutical company specializing in the development and commercialization of products for the treatment of central nervous system (CNS) diseases. The company's portfolio includes a range of medications targeting epilepsy and attention deficit hyperactivity disorder (ADHD).
SUPN's stock price history has shown steady growth over the years. The company's stock has experienced both upward and downward trends, but overall, it has shown resilience and has been able to recover from any setbacks.
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Mr. Jack A. Khattar
Headquarters
Rockville
Employees
612
Exchange
NASDAQ
add Supernus Pharmaceuticals  to watchlist

Keep an eye on Supernus Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Supernus Pharmaceuticals 's (SUPN) price per share?

The current price per share for Supernus Pharmaceuticals (SUPN) is $31.26. The stock has seen a price change of $0.12 recently, indicating a 0.38% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Supernus Pharmaceuticals (SUPN)?

For Supernus Pharmaceuticals (SUPN), the 52-week high is $42.5, which is 35.96% from the current price. The 52-week low is $21.99, the current price is 42.16% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Supernus Pharmaceuticals (SUPN) a growth stock?

Supernus Pharmaceuticals (SUPN) has shown an average price growth of -1.65% over the past three years. It has received a score of 53 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Supernus Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Supernus Pharmaceuticals (SUPN) stock price performance year to date (YTD)?

As of the latest data, Supernus Pharmaceuticals (SUPN) has a year-to-date price change of -13.55%. Over the past month, the stock has experienced a price change of -20.07%. Over the last three months, the change has been -14.33%. Over the past six months, the figure is -0.7%. Looking at a longer horizon, the five-year price change stands at 107.85%.
help

Is Supernus Pharmaceuticals (SUPN) a profitable company?

Supernus Pharmaceuticals (SUPN) has a net income of $73.86M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.23% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 11.23% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $661.82M, with a revenue growth rate of 8.94%, providing insight into the company's sales performance and growth. The gross profit is $583.91M. Operating income is noted at $81.67M. Furthermore, the EBITDA is $172.17M.
help

What is the market capitalization of Supernus Pharmaceuticals (SUPN)?

Supernus Pharmaceuticals (SUPN) has a market capitalization of $1.74B. The average daily trading volume is 31.3, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level